Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)92-98
Number of pages7
JournalEuropean Journal of Cancer
Volume91
DOIs
Publication statusPublished - 1 Mar 2018

Keywords

  • Non-small cell lung cancer
  • Tyrosine kinase inhibitor
  • QT interval
  • Disease flare
  • Drug monitoring
  • CELL LUNG-CANCER
  • 1ST-LINE TREATMENT
  • PHASE-3 TRIAL
  • OPEN-LABEL
  • GEFITINIB
  • ADENOCARCINOMA
  • DACOMITINIB
  • INHIBITOR
  • ERLOTINIB
  • INTERVAL

Cite this